Edgewise Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
EWTX$46.53-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(In thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · Common Stock · · Additional · · Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| · Shares · Amount · Paid-In Capital · Loss · Deficit · Total | |||||||||||||||||
| Balance as of December 31, 2023 | 70,453,342 | | $7 | | $563,487 | | $99 | | $(244,763) | | $318,830 | ||||||
| Issuance of common stock, net of offering costs | | 22,450,206 | | | 2 | | | 238,797 | | | — | | | — | | | 238,799 |
| Exercise of stock options | 380,980 | | — | | 1,926 | | | — | | — | | 1,926 | |||||
| Stock-based compensation | — | | — | | 4,871 | | | — | | — | | 4,871 | |||||
| Other comprehensive loss | | — | | — | | — | | | (960) | | — | | (960) | ||||
| Net loss | | — | | — | | — | | | — | | (28,525) | | (28,525) | ||||
| Balance as of March 31, 2024 | 93,284,528 | | $9 | | $809,081 | | $(861) | | $(273,288) | | $534,941 | ||||||
| · · · · · · · · · · · · · · · · · | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · | |||||||||||||
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||
| · · Common Stock · · Additional · · Other Comprehensive · · Accumulated · · · | |||||||||||||
| · Shares · Amount · Paid-In Capital · Income · Deficit · Total | |||||||||||||
| Balance as of December 31, 2024 | | 94,838,466 | | $9 | | $837,363 | | $420 | | $(378,576) | | $459,216 | |
| Exercise of stock options | 367,217 | | — | | 2,261 | | | — | | — | | 2,261 | |
| Stock-based compensation | — | | — | | 9,059 | | | — | | — | | 9,059 | |
| Other comprehensive loss | — | | — | | — | | | (19) | | — | | (19) | |
| Net loss | — | | — | | — | | | — | | (40,798) | | (40,798) | |
| Balance as of March 31, 2025 | 95,205,683 | | $9 | | $848,683 | | $401 | | $(419,374) | | $429,719 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.